Carolyn Rynard is a Principal Scientist at Cardinal Health Regulatory Sciences, and has over thirty years’ experience in drug, device, combination product and biologic product development. Drug development experience is from the research stage through nonclinical, clinical, commercial, and postapproval stages for drugs and devices.
In her prior position Dr. Rynard was Vice President of Product Development at Halozyme Therapeutics and oversaw the development and approval of drugs and devices. Previous positions include Vice President of Product Development at Medinox, Inc., Senior Director Product Development at Amylin Pharmaceuticals, and research scientist positions at Baxter Healthcare and Du Pont. Dr. Rynard is a Stanford University graduate with a Ph.D. degree in Physical Chemistry.